Compare Gilead Sciences, Inc. (GILD) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

HPE stock declined 8.45% to $45.37 amid a broader AI hardware sector pullback, though technical indicators remain bullish with strong support at $45. The company shows solid fundamentals with three consecutive earnings beats and robust AI infrastructure demand driving a record $6B backlog. Revenue grew to $34.3B in 2025 while maintaining a 33.9% gross margin, though net income dropped significantly to $57M due to acquisition-related costs.

HPE presents a compelling opportunity with analyst consensus target of $69.69 (54% upside) and strong AI infrastructure positioning, but faces execution risks from the Juniper integration and volatile cash flow trends. The stock's current valuation at 44.29 P/E appears elevated relative to historical norms, requiring careful monitoring of margin expansion and debt management.